portfolio

marc vaillancourt

HARD WORKERVIAGRA patients and the confidence of experience

• VIAGRA users (n=147) achieved erections hard enough for penetration (EHS 3 or 4) on 85% of occasions vs. 57% for placebo (n=147) (p<0.0001)1,†

• Completely hard, EHS 4 erections were achieved on an estimated 58% of occasions by VIAGRA users (n=140) vs. 14% for placebo (n=142) (p<0.0001)2,†

The confidence of experience

PrVIAGRA® is indicated for the treatment of erectile dysfunction, which is the inability to achieve or maintain a penile erection sufficient for satisfactory sexual performance.3

Most frequently reported adverse events in controlled clinical trials were headache (15.8%), flushing (10.5%), dyspepsia (6.5%), nasal congestion (4.2%) and abnormal vision (2.7%).3

Treatments for erectile dysfunction should generally not be used in men for whom sexual activity is inadvisable.3

VIAGRA has been shown to potentiate the hypotensive effects of nitrates in healthy volunteers and in patients, and is therefore contraindicated in patients who are taking any type of nitrate drug therapy, or who utilize short-acting nitrate-containing medications, due to the risk of developing potentially life-threatening hypotension. The use of organic nitrates, either regularly and/or intermittently, in any form (e.g., oral, sublingual, transdermal, by inhalation) is absolutely contraindicated.3

Postmarketing reports of sudden loss of vision have occurred rarely. It is not clear whether these are related directly to the use of PDE5 inhibitors or to other factors. There may be an increased risk to patients who have already experienced Non-Arteritic Anterior Ischemic Optic Neuropathy. Patients should stop taking VIAGRA and consult their physician if they experience a decrease in, or loss of, vision in one or both eyes. Physicians should advise patients to stop taking Viagra and seek prompt medical attention in case of sudden decrease or loss of hearing.3

† Double-blind, placebo-controlled, flexible-dose study. 307 patients were randomized to receive sildenafil 25-100 mg (n=154) or placebo (n=153) for 6 weeks, with an open-label extension of 6 weeks. Data shown is from the 6-week, double-blind, placebo-controlled portion of the study. Erection hardness was measured with the Erection Hardness Score (EHS) using an event log, in which men were asked to record the hardness of their erections based on a four-point scale. The percentage of occasions with EHS 3 or 4 was similar between the sildenafil (45%) and placebo (46%) groups. At the end of double-blind placebo-controlled treatment the percentage of occasions with EHS 3 or 4 had increased significantly more (p<0.0001) in the sildenafil versus placebo group (LS mean + SE, 40% + 3% vs. 11% + 3%), and the estimated percentage of occasions with EHS 4 was 58% (95% CI, 52-65%) vs. 14% (95% CI, 10-19%) compared to baseline values of 5.2% and 5.1% (odds ratio, 8.5; p<0.0001).

2Penis is hard enough for penetration but not completely hard

3Penis is hard, but not hard enough or penetration

4Penis is larger, but not hard

Erection Hardness Scale (EHS):

1Penis is completely hard and fully rigid

The confidence of experience

A score of 3 or 4 on the Erection Hardness Scale is what many ED patients hope for. PrVIAGRA® may help tip the odds in their favour.

• VIAGRA users (n=147) achieved erections hard enough for penetration (EHS 3 or 4) on 85% of occasions vs. 57% for placebo (n=147) (p<0.0001)1,†

• Completely hard, EHS 4 erections were achieved on an estimated 58% of occasions by VIAGRA users (n=140) vs. 14% for placebo (n=142) (p<0.0001)2,†

PrVIAGRA® is indicated for the treatment of erectile dysfunction, which is the inability to achieve or maintain a penile erection sufficient for satisfactory sexual performance.3

Most frequently reported adverse events in controlled clinical trials were headache (15.8%), flushing (10.5%), dyspepsia (6.5%), nasal congestion (4.2%) and abnormal vision (2.7%).3

Treatments for erectile dysfunction should generally not be used in men for whom sexual activity is inadvisable.3

VIAGRA has been shown to potentiate the hypotensive effects of nitrates in healthy volunteers and in patients, and is therefore contraindicated in patients who are taking any type of nitrate drug therapy, or who utilize short-acting nitrate-containing medications, due to the risk of developing potentially life-threatening hypotension. The use of organic nitrates, either regularly and/or intermittently, in any form (e.g., oral, sublingual, transdermal, by inhalation) is absolutely contraindicated.3Postmarketing reports of sudden loss of vision have occurred rarely. It is not clear whether these are related directly to the use of PDE5 inhibitors or to other factors. There may be an increased risk to patients who have already experienced Non-Arteritic Anterior Ischemic Optic Neuropathy. Patients should stop taking VIAGRA and consult their physician if they experience a decrease in, or loss of, vision in one or both eyes. Physicians should advise patients to stop taking Viagra and seek prompt medical attention in case of sudden decrease or loss of hearing.3

*Individual case. May not be representative of results in the general population.† Double-blind, placebo-controlled, flexible-dose study. 307 patients were randomized to receive sildenafil 25-100 mg (n=154) or placebo (n=153) for 6 weeks, with an open-label extension of 6 weeks. Data shown is from the 6-week, double-blind, placebo-controlled portion of the study. Erection hardness was measured with the Erection Hardness Score (EHS) using an event log, in which men were asked to record the hardness of their erections based on a four-point scale. The percentage of occasions with EHS 3 or 4 was similar between the sildenafil (45%) and placebo (46%) groups. At the end of double-blind placebo-controlled treatment the percentage of occasions with EHS 3 or 4 had increased significantly more (p<0.0001) in the sildenafil versus placebo group (LS mean + SE, 40% + 3% vs. 11% + 3%), and the estimated percentage of occasions with EHS 4 was 58% (95% CI, 52-65%) vs. 14% (95% CI, 10-19%) compared to baseline values of 5.2% and 5.1% (odds ratio, 8.5; p<0.0001).

2Penis is hard enough for penetration but not completely hard

3Penis is hard, but not hard enough or penetration

4Penis is larger, but not hard

Erection Hardness Scale (EHS):

1Penis is completely hard and fully rigid

HARD WORKERVIAGRA patients and the confidence of experience

• VIAGRA users (n=147) achieved erections hard enough for penetration (EHS 3 or 4) on 85% of occasions vs. 57% for placebo (n=147) (p<0.0001)1,†

• Completely hard, EHS 4 erections were achieved on an estimated 58% of occasions by VIAGRA users (n=140) vs. 14% for placebo (n=142) (p<0.0001)2,†

The confidence of experience

PrVIAGRA® is indicated for the treatment of erectile dysfunction, which is the inability to achieve or maintain a penile erection sufficient for satisfactory sexual performance.3

Most frequently reported adverse events in controlled clinical trials were headache (15.8%), flushing (10.5%), dyspepsia (6.5%), nasal congestion (4.2%) and abnormal vision (2.7%).3

Treatments for erectile dysfunction should generally not be used in men for whom sexual activity is inadvisable.3

VIAGRA has been shown to potentiate the hypotensive effects of nitrates in healthy volunteers and in patients, and is therefore contraindicated in patients who are taking any type of nitrate drug therapy, or who utilize short-acting nitrate-containing medications, due to the risk of developing potentially life-threatening hypotension. The use of organic nitrates, either regularly and/or intermittently, in any form (e.g., oral, sublingual, transdermal, by inhalation) is absolutely contraindicated.3

Postmarketing reports of sudden loss of vision have occurred rarely. It is not clear whether these are related directly to the use of PDE5 inhibitors or to other factors. There may be an increased risk to patients who have already experienced Non-Arteritic Anterior Ischemic Optic Neuropathy. Patients should stop taking VIAGRA and consult their physician if they experience a decrease in, or loss of, vision in one or both eyes. Physicians should advise patients to stop taking Viagra and seek prompt medical attention in case of sudden decrease or loss of hearing.3

† Double-blind, placebo-controlled, flexible-dose study. 307 patients were randomized to receive sildenafil 25-100 mg (n=154) or placebo (n=153) for 6 weeks, with an open-label extension of 6 weeks. Data shown is from the 6-week, double-blind, placebo-controlled portion of the study. Erection hardness was measured with the Erection Hardness Score (EHS) using an event log, in which men were asked to record the hardness of their erections based on a four-point scale. The percentage of occasions with EHS 3 or 4 was similar between the sildenafil (45%) and placebo (46%) groups. At the end of double-blind placebo-controlled treatment the percentage of occasions with EHS 3 or 4 had increased significantly more (p<0.0001) in the sildenafil versus placebo group (LS mean + SE, 40% + 3% vs. 11% + 3%), and the estimated percentage of occasions with EHS 4 was 58% (95% CI, 52-65%) vs. 14% (95% CI, 10-19%) compared to baseline values of 5.2% and 5.1% (odds ratio, 8.5; p<0.0001).

2Penis is hard enough for penetration but not completely hard

3Penis is hard, but not hard enough or penetration

4Penis is larger, but not hard

Erection Hardness Scale (EHS):

1Penis is completely hard and fully rigid

Bring PrVIAGRA® and the Erection Hardness Scale into play for your ED patients.

• VIAGRA users (n=147) achieved erections hard enough for penetration (EHS 3 or 4) on 85% of occasions vs. 57% for placebo (n=147) (p<0.0001)1,†

• Completely hard, EHS 4 erections were achieved on an estimated 58% of occasions by VIAGRA users (n=140) vs. 14% for placebo (n=142) (p<0.0001)2,†

The confidence of experience

PrVIAGRA® is indicated for the treatment of erectile dysfunction, which is the inability to achieve or maintain a penile erection sufficient for satisfactory sexual performance.3

Most frequently reported adverse events in controlled clinical trials were headache (15.8%), flushing (10.5%), dyspepsia (6.5%), nasal congestion (4.2%) and abnormal vision (2.7%).3

Treatments for erectile dysfunction should generally not be used in men for whom sexual activity is inadvisable.3

VIAGRA has been shown to potentiate the hypotensive effects of nitrates in healthy volunteers and in patients, and is therefore contraindicated in patients who are taking any type of nitrate drug therapy, or who utilize short-acting nitrate-containing medications, due to the risk of developing potentially life-threatening hypotension. The use of organic nitrates, either regularly and/or intermittently, in any form (e.g., oral, sublingual, transdermal, by inhalation) is absolutely contraindicated.3

Postmarketing reports of sudden loss of vision have occurred rarely. It is not clear whether these are related directly to the use of PDE5 inhibitors or to other factors. There may be an increased risk to patients who have already experienced Non-Arteritic Anterior Ischemic Optic Neuropathy. Patients should stop taking VIAGRA and consult their physician if they experience a decrease in, or loss of, vision in one or both eyes. Physicians should advise patients to stop taking Viagra and seek prompt medical attention in case of sudden decrease or loss of hearing.3

† Double-blind, placebo-controlled, flexible-dose study. 307 patients were randomized to receive sildenafil 25-100 mg (n=154) or placebo (n=153) for 6 weeks, with an open-label extension of 6 weeks. Data shown is from the 6-week, double-blind, placebo-controlled portion of the study. Erection hardness was measured with the Erection Hardness Score (EHS) using an event log, in which men were asked to record the hardness of their erections based on a four-point scale. The percentage of occasions with EHS 3 or 4 was similar between the sildenafil (45%) and placebo (46%) groups. At the end of double-blind placebo-controlled treatment the percentage of occasions with EHS 3 or 4 had increased significantly more (p<0.0001) in the sildenafil versus placebo group (LS mean + SE, 40% + 3% vs. 11% + 3%), and the estimated percentage of occasions with EHS 4 was 58% (95% CI, 52-65%) vs. 14% (95% CI, 10-19%) compared to baseline values of 5.2% and 5.1% (odds ratio, 8.5; p<0.0001).

YOU DON’T HAVE TO GO THIS FAR

TO SAVE UP TO 3%* ON FUEL…

The right choice in lubricants

...WITH TOTAL FUEL ECONOMY LUBRICANTSOur field-proven Fuel Economy lubricants can reduce your fuel consumption by up to 3%* while lowering CO2 emissions. Using TOTAL RUBIA FE engine oils combined with TOTAL Synthetic Gear and Axle lubricants translates to a saving of over $1,000* per truck per year! www.total-fe.com* Results verified by both US and European labs, in comparison with standard lubricants. Figures may vary depending on multiple factors. Simulations use fuel cost at $0.95/L, 125 000 Km/year, average fuel consumption of 43L/100Km. See www.total-lubricants.ca for further details.

Cre

dit

s:

lxb

.ca

an

d g

len

np

yke

stu

dio

.co

m

RecommendAccu-chEk Empowers your patients to manage their diabetes throughout their entire life.

Tracking Today and Tomorrow

The world’s first strip-free device empowers you to manage your diabetes routinely and effectively

Tracking Today and Tomorrow

La facilité du tout-en-un qui donne le pouvoir à vos patients de contrôler efficacement leur diabète durant toute leur vie.

Définir aujourd’hui et demain

Tracking Today and Tomorrow

Ask for Accu-chek Empowers you to manage your diabetes throughout your entire life.

g force

Innovative Net Kreations

Ajoutez-y votre touche

personnelle

Mille et une idées qui embelliront votre décor

C’est l’heure d’aller

au

107 idées de chambre à coucher à faire rêver

litSoyez

branchéDes idées électrisantes pour vous simplifier la vie

Dormez sur vos deux

oreilles

67 idées confort pour vous souhaiter une bonne nuit

We can point you in the right direction.

Are you reAdy for the journey?

Could you go the distance?

Why is the road to quitting so difficult?

Welcome to the crossroads to quitting.

Let’s get going the road to success starts here

taking a trip to your doctor

Speak to your doctor.

Quitting smoking is one of the toughest

thing you will ever do. In fact, most smokers

try to quit at least several times before they

finally succeed. Nicotine replacement ther-

apy gives you the ammunition you need to

make quitting stick. Nicorette gives you the

flexibility of chewing an extra piece when

the cravings get too hard to handle while

Nicoderm provides a continuous defense

against those cravings.

Quitting smoking is one of the toughest

thing you will ever do. In fact, most smokers

try to quit at least several times before they

finally succeed. Nicotine replacement ther-

apy gives you the ammunition you need to

make quitting stick. Nicorette gives you the

flexibility of chewing an extra piece when

the cravings get too hard to handle while

Nicoderm provides a continuous defense

against those cravings.

marc vaillancourt / 514 484 3994

355